Reference | Region | Location/data collection period | Locally advanced stage of cervical cancer | N | Histologic group |
Garg et al*8 2011 | North America | USA 1988–2005 | IIA1 | 271 | SCC, 79.7% AC, 13.3% ASC, 7.0% |
IIA2 | 289 | SCC, 83.0% AC, 12.8% ASC, 4.2% | |||
Tian et al†9 2020 | North America | USA 2010–2015 | IB2, 10.8% IIA1, 2.4% IIA2, 4.0% IIB, 21.6% IIIA, 2.2% IIIB, 54.3% IVA, 4.7% | 3385 | SCC |
IB2, 19.0% IIA1, 3.4% IIA2, 5.6% IIB, 21.4% IIIA, 2.0% IIIB, 46.4% IVA, 2.1% | 746 | AC | |||
Carmo et al18 2011 | South America | Brazil Rio de Janeiro 1999–2004 | II | 1133 | SCC, 83.3% AC, 12.9% ASC, 3.8% |
III | 1216 | SCC, 89.1% AC, 8.4% ASC, 2.5% | |||
Agarwal et al19 2012 | Asia | India Delhi 2000–2009 | II | 306 | SCC, 92.8% AC, 5.6% Other, 1.6% |
III | 328 | SCC, 95.4% AC, 4.3% Other, 0.3% | |||
Shruthi et al7 2014 | Asia | India Kolar 1-year period (date not reported) | IIB | 29 | WDSCC, 17.2% MDSCC, 69.0% PDSCC, 13.8% AC, 0 |
IIIB | 151 | WDSCC, 17.9% MDSCC, 57.6% PDSCC, 21.9% AC, 2.6% | |||
IVA | 14 | WDSCC, 0 MDSCC, 0 PDSCC, 100% AC, 0 |
*The Garg 2011 study8 only included patients with stage IIA cervical cancer, with analyses comparing IIA1 and IIA2.
†The Tian 2020 study9 only included patients with locally advanced stages of cervical cancer and squamous cell or adenocarcinoma histology; patients with squamous cell and adenocarcinoma histology were separated for all analyses.
AC, adenocarcinoma; ASC, adenosquamous carcinoma; MDSCC, moderately differentiated squamous cell carcinoma; PDSCC, poorly differentiated squamous cell carcinoma; SCC, squamous cell carcinoma; WDSCC, well-differentiated squamous cell carcinoma.